Shares up 12-fold in 3 months, Jiuan executives interviewed, Can investors claim compensation?

2022-07-22 0 By

Three months after the stock price ran wild, a letter of supervision fell to the “super monster” Jiuan Medical (002432.SZ) head.On the evening of February 14, Jiuan medical announced that its chairman and general manager Liu Yi and board secretary Wu Tong had been placed under supervision by tianjin Securities Regulatory Bureau due to incomplete information disclosure.Red Star Capital bureau found that the regulatory authorities referred to the matter, the results of an experiment in early 2022 disclosure.On January 7, The company announced that a home self-test kit for COVID-19 detected 100% of active Omicron virus samples with a maximum CT value of 21.59(n=5) in experiments.However, after the Shenzhen Securities regulatory Bureau issued a letter of inquiry, Jiuan medical announced that the experimental data will be complete, that is to say, “100% detection rate” is only part of the experimental results.Investors have questioned this: “Jiuan medical disclosure of experimental results only said good not bad”, “disclosure of experimental data can be choosy?”On February 15, Red Star Capital Bureau called the securities department of Jiuan Medical, and the relevant staff still said: “We have explained in the reply letter on January 15 that no letter is complete”.In addition, The Tianjin Securities Regulatory Bureau required Liu Yi and Wu Tong to attend the regulatory conversation in tianjin Securities Regulatory Bureau before February 18. The staff of the Securities Department said that they had not decided when to go (the regulatory conversation) and did not know the content of the regulatory conversation.Earlier, due to the popularity of the novel coronavirus test concept, Jiuan Medical’s share price rose more than 12 times in less than three months, and was dubbed by shareholders as “the strongest monster stock in the past year”.As the stock soared, Jiuan was also questioned by the market about whether a home COVID-19 test could sustain such a high rise.Are stock prices wildly out of step with fundamentals?Is there a hot money hype?Because of the letter letter problem two executives were interviewed jiuan medical staff insisted: letter letter no problem nine medical letter letter what happened?Red Star Capital Bureau found that the matter stemmed from the disclosure of the results of an experiment in early 2022.As can be seen from the Decision on Administrative Supervision Measures issued by Tianjin Securities Regulatory Bureau, “After investigation, Jiuan Medical only disclosed part of the experimental results of successful testing on January 7, but did not disclose all the experimental results, and the disclosure information was incomplete.”Red Star Capital Bureau noted that in the announcement on January 7, Jiuan Medical disclosed an experiment report of a self-test kit of its subsidiary for THE novel coronavirus against the Omicron variant virus, and said that the report showed that the kit detected 100% of active Omicron virus samples with a maximum CT value of 21.59(n=5) in the experiment.On the day of the announcement, jiuan medical shares have risen 6.05%;Subsequently, its in January 11 -17 consecutive close 5 daily limit.In other words, jiuan’s estimate rose 74% in just seven trading days, which is rare.On January 18, the share price of Jiuan Medical was 88.88 yuan per share.In attracting the attention of the market at the same time, Jiuan medical also attracted the attention of the regulatory level.On January 12, the shenzhen stock exchange issued inquiry letter to the nine medical series 7 salute, proposed “the existence of sample with some samples of positive detection rate to all positive detection rate of misleading investors, the announcement of the disclosure of the result of the experiment report test is complete, if there is a selective disclosure of information to hype stock situation” and so on.On January 15, Jiuan Medical replied to the above letter of concern. The most important thing is to make up the positive detection rate of all experimental groups required by shenzhen Stock Exchange: “When CT value ≤21.59, all can be detected; when CT value is 22.86, 60% can be detected; when CT value ≥23.87, it cannot be detected at all.”The company also said, 100 percent of the active Omicron virus samples were detected with a maximum CT value of 21.59(n=5). The maximum means that 100 percent of the active Omicron virus samples with a CT value of less than or equal to 21.59 can be detected, while those with a CT value greater than 21.59 cannot be.In other words, “100% detection rate” is only part of the experimental results.Investors questioned: “Jiuan medical disclosure of experimental results only said good not bad”, “disclosure of experimental data can be choosy?”However, Jiuan medical does not admit that the letter is incomplete: “The company used the brief wording in the announcement is based on the consideration of the incomprehension problems caused by too many professional terms in the announcement, but in terms of the understandable wording and integrity, the relevant provisions really need to be improved.”But from the “decision book” issued last night, it can be seen that tianjin Securities regulatory Bureau does not agree with such a view.On February 15, Red Star Capital Bureau called the securities department of Jiuan Medical, and the relevant staff still said: “We have already explained in the reply letter on January 15 that no letter is incomplete.”Regarding the question that The Tianjin Securities Regulatory Bureau required Liu Yi and Wu Tong to attend the regulatory conversation in tianjin Securities Regulatory Bureau before February 18, the staff of the Securities Department said that they had not yet decided when to go (the regulatory conversation) and did not know much about the content of the regulatory conversation.From the end of last year to now, Jiuan Medical has been the “star stock” in the capital market, also known as “the strongest trans-year monster stock” due to the rapid rise of its share price.Established in 1995, Jiuan Medical is mainly engaged in the research and development, production and sales of household medical and health electronic products, mainly producing and selling household health equipment.In June 2010, Jiuan Medical successfully IPO, but after the listing, the performance of Jiuan medical alternating losses and profits, A stock market is not conspicuous.Until November 8, 2021, Jiuan Disclosed that its subsidiary’s iHealth home-use COVID-19 test kit was authorized for emergency use in the United States.The advantages of the product lie in that it can be collected by individuals, the results can be obtained quickly in 15 minutes, and it can be purchased without prescription through e-commerce, drugstores, supermarkets and other channels in America.According to the company’s estimate, production capacity will reach 200 million people per month in early 2022.From November 11 to 15, 2021, Jiuan Medical continuously exposed good news on the interactive easy platform, jiuan medical’s stock price began to trend, and consecutive harvest of a number of daily limit, so that countless shareholders are astounded.From the stock price trend chart, on November 15, 2021, near the close, Jiuan Medical was suddenly hit by a huge amount of capital, instant trading;On The 16th, the stock price opened slightly higher and rose by the daily limit again.17, a word limit;18, trading limit;19, trading limit;Followed by 22 -25 days, continuous word board limit;On The 26th, the stock price rise only slightly moderated.By November 26, 2021, Jiuan Medical has risen from 6.9 yuan/share to 15.67 yuan/share, up to 127%.Then from November 29, 2021 to December 1, 2021, Jiuan Medical is three trading limits, and the stock price keeps setting new highs.However, the “wild run” of Jiuan medical stock price did not stop here, and continued to climb in December 2021.According to the preliminary statistics of Red Star Capital Bureau, from November 15 to December 30, 2021, Jiuan Medical has risen by the daily limit in 23 trading days out of 34 trading days, with a cumulative increase of more than 7 times.At the beginning of the New Year of 2022, the share price of Jiuan Medical continued to rise strongly and reached the peak of 88.88 yuan/share on January 18, 2022.From November 15 last year to now, the stock price rose more than 12 times in just 3 months, including 28 daily limit board, investors dubbed it as “the biggest monster stock in the year”.The profit brought by the kit exceeds the total of 11 years listed shareholders questioned whether the shin PI problem can be claimed?As the stock soared, Jiuan was also questioned by the market about whether a home COVID-19 test could sustain such a high rise.Are stock prices wildly out of step with fundamentals?Is there a hot money hype?It was not until the outbreak of COVID-19 in 2020 that Jiuan Medical began to export thermometer and other epidemic prevention products to foreign countries that both its operating income and net profit soared.In 2020, it achieved operating revenue of 2.008 billion yuan, up 184.36% year-on-year, and net profit of 242 million yuan, up 264.68% year-on-year.Despite the obvious performance growth, but in 2020, the share price of Jiuan Medical has always been hovering below 10 yuan.Before this, jiuan medical performance has always been in a “tepid” state.In terms of financial results, jiuan Medical, in its first year of listing, had an operating revenue of 299 million yuan in 2010, down 4.62% year on year;Net profit of 24 million yuan, down 39.25%;Non-deduction net profit of 20 million yuan, down 46.76% year-on-year.In the following 12 years, Jiuan medical performance is profit and loss alternation.Red Star Capital Bureau through jiuan medical financial results found that in 2010 jiuan medical net profit of 20.8067 million yuan;In 2012, the net profit dropped to 6.9829 million yuan.In 2013, the net profit became -9.1683 million yuan;In 2014, the net profit turned positive and was 10,197,500 yuan;The net profit in 2015 was negative again, -151 million yuan;In 2016, 14.4979 million yuan;In 2017, it was -166 million yuan;In 2018, 12,686,800 yuan;In 2019, it was 66.4491 million yuan.On January 20, Jiuan Medical released its 2021 performance report, which is expected to make a profit of 900-1.2 billion yuan in 2021, up 271%-395%.It is worth noting that last year’s quarterly report showed that jiuan medical net profit in the first three quarters of 2021 was 50.128 million yuan.In other words, in the fourth quarter of 2021 alone, its net profit reached 849 million yuan to 1.149 billion yuan, which has exceeded the total net profit since it went public.According to the announcement of Jiuan Medical, the reason for the growth is that the sales of the company’s Novel Coronavirus (SARS-CoV-2) antigen home self-testing OTC kit in the US market increased significantly, which contributed to the significant growth in the operating performance in 2021.Red Star Capital bureau noted that the number of shareholders of Jiuan Medical increased from just over 60,000 to 179,000 from the end of the third quarter of last year to the end of the fourth quarter after the positive news about the home test box.In jiuan medical stock bar, many investors for Jiuan medical are hot state.But after hitting its peak on January 18, Jiuan’s share price began to fluctuate and fell by more than 35% from its peak to 56.91 yuan on February 15.Red Star Capital Bureau found that recently investors commented that their investment was damaged because of the shin PI problem, can you claim for compensation to Jiuan Medical?, red star capital bureau had an interview with the sichuan ShengHao law firm focused on shareholder rights and interests protection Hao Huizhen lawyer, she said, according to the measures for the administration of information disclosure of listed companies (order no. 182 of the securities regulatory commission) in article 3, the listed company information disclosure shall be truthful, accurate and complete, and nine medical Ann in January 7, 2022, the information disclosure is not complete,In violation of this regulation, there are omissions in information disclosure.Lawyer Hao further pointed out:”However, when Jiuan Medical replied to the letter of concern from Shenzhen Stock Exchange on January 15, it made supplementary disclosure. The disclosure of this information did not adversely affect the stock price trend of Jiuan Medical on January 17, and the stock price remained trading at the daily limit. Therefore, according to the relevant judicial interpretation,Jiuan medical’s information disclosure violation in this matter has no causal relationship with the stock price decline after January 18, and the probability of successful claims by investors is not high.”In addition, MAO Wei, director of the capital market legal affairs department of Beijing Law Firm, analyzed red Star Capital bureau: “If the information is not disclosed at all or falsely disclosed, such violations will be punished by the regulatory authorities.But Jiuan medical is not complete disclosure, the regulatory authorities are only interview, is a minor violation.”MAO Wei also said that in this case, it is impossible to prove that such a degree of violation is directly related to the loss, and it is difficult to implement the compensation for the loss from the perspective of laws and regulations. “The degree of violation determines the degree of punishment for their compensation, and the probability of success of investors’ claim is not high,” MAO said.Red Star news reporter Yu Yaoqiang Ya Milling editor Yu Dongmei (download Red Star news, the report has a prize!